Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Development & Bioavailability
  6.  » Reducing Risks In Early Drug Development: From Drug Candidate to Phase 1 Clinical Testing
Webinar icon

Reducing Risks In Early Drug Development: From Drug Candidate to Phase 1 Clinical Testing

Summary: Achieving success in early development is essential in progressing a drug molecule’s next milestone. Such pressure can often lead to the adoption of short-term thinking and overlook the downstream realities of drug development. Although solubility challenges are significant hurdles to overcome, there are additional biopharmaceutical challenges to consider during the path to clinic. Addressing issues early and comprehensively in the development life-cycle can result in fewer problems down the line such as escalating timelines, reformulating issue due to ADMEs issues, costs and regulatory issues. Therefore, It is important to leverage the skills and experiences of pharmaceutical scientists at the earliest stages of development to optimize and enable drug candidates to reach their true potential.

View the webinar